J Allergy Clin Immunol, 71: 473-480
How Elecoglipron Compares to Other Oral GLP-1s If approved, elecoglipron would enter a rapidly evolving oral GLP-1 category that currently has two major contenders
Real-world data are valuable, both for regulators and for healthcare professionals making choices about treatment options
Your weight loss history not a formal report, just a mental note of what youve tried before (diets, programs, medications) and what happened
The Outcome Reduction with Initial Glargine Intervention trial (i.e., ORIGIN) was an open-label, randomized, 12,537 patient study that compared LANTUS to standard care on the time to first occurrence of a major adverse cardiovascular event (MACE)
Once healing is established, nasal spray maintains support more conveniently